Gold prices steady ahead of Fed decision; weekly weakness noted
Hakan Kardes, the Chief Experience Officer at Alignment Healthcare, Inc. (NASDAQ:ALHC), recently executed a series of stock transactions involving the company’s common stock. The sales come as the company’s shares have shown remarkable strength, gaining over 250% in the past year and currently trading near their 52-week high of $17.27. According to a filing with the Securities and Exchange Commission, Kardes sold a total of 31,602 shares over two days, amounting to approximately $533,471.
On March 18, Kardes sold 25,000 shares at an average price of $17.0077, totaling $425,192. The following day, March 19, he sold an additional 6,602 shares at prices ranging from $16.088 to $16.9588, generating $108,279. The transactions occurred as Alignment Healthcare, now valued at $3.3 billion, has demonstrated strong revenue growth of 48% over the last twelve months.
These transactions were conducted under a Rule 10b5-1 trading plan, which Kardes adopted on March 14, 2024. The sales were made to cover tax withholding obligations related to the vesting of restricted stock units, rather than discretionary trades. Following these transactions, Kardes retains ownership of 686,212 shares of Alignment Healthcare’s common stock. For deeper insights into ALHC’s valuation and growth prospects, InvestingPro subscribers can access exclusive analysis and 11 additional ProTips about the company’s financial health and market position.
In other recent news, Alignment Healthcare reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an EPS of -0.16 compared to the forecast of -0.18. The company’s revenue also exceeded projections, reaching $701.2 million against the expected $674.97 million. For the full year, Alignment Healthcare’s revenue hit $2.7 billion, marking a 48% increase year-over-year. The company achieved its first year of adjusted EBITDA profitability, a significant milestone, with membership growing by 59% in 2024. Looking ahead, Alignment Healthcare has provided guidance for 2025, projecting revenue between $3.72 billion and $3.78 billion, with adjusted gross profit expected to range from $415 million to $445 million.
Additionally, Piper Sandler raised its price target for Alignment Healthcare to $21, maintaining an Overweight rating, citing the company’s scalable "flywheel" approach as a key driver for success. Similarly, Raymond (NSE:RYMD) James increased its price target to $19, up from the previous $14, while reiterating a Strong Buy rating following the company’s robust fourth-quarter performance. Analyst John Ransom from Raymond James highlighted Alignment Healthcare’s ability to grow annually at a rate of 20% or more while enhancing EBITDA profitability. These recent developments reflect investor confidence in Alignment Healthcare’s growth trajectory and its ability to deliver better-than-expected financial results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.